Clinical trial
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic…
NCT00096018 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00096018 |
|---|---|
| Title | Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia |
| Official title | A Phase I/II Study of Fludarabine Plus Thalidomide as Frontline Therapy for Newly Diagnosed Patients With Chronic Lymphocytic Leukemia |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | fludarabine phosphate, thalidomide |
| Enrollment | 43 |
| Start date | May 1, 2002 |
| Primary completion | Nov 1, 2010 |
| Completion | May 1, 2012 |
| First posted | Nov 9, 2004 |
| Last update posted | Oct 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: